Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — Affordable Medicines and Generic Pharmacies (UPSC Indian Society)

Medicines account for a large share of out-of-pocket health expenditure in India — roughly 60-70% of OOPE. A fever, a fracture or a chronic condition can push a family into debt even without hospitalisation. The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is the government's most direct intervention on this frontier — a network of generic-medicine stores selling quality drugs at a fraction of branded prices.

This guide explains PMBJP's architecture, progress, quality safeguards and contemporary debates.

What is PMBJP?

PMBJP (earlier Jan Aushadhi Scheme, launched 2008; relaunched and rebranded in 2015-16) aims to:

• Make quality medicines available at affordable prices.
• Promote generic equivalents of branded medicines.
• Reduce out-of-pocket expenditure on medicines.
• Establish Jan Aushadhi Kendras (JAKs) across India.

Administered by:

• Pharmaceuticals & Medical Devices Bureau of India (PMBI) — implementing agency.
• Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.

Scale and Reach

• JAKs operational — over 12,500 by late 2024 (target: 25,000 by 2026).
• Product basket — 2,000+ medicines and 300+ surgical and consumables.
• Target reach — at least one kendra in every block of every district.
• Geographic coverage — expanding into tier-II and tier-III cities, rural areas, aspirational districts.

Pricing and Savings

• Prices fixed at 50-80% below market rates of branded equivalents.
• Cumulative savings to consumers estimated at over Rs 28,000 crore since inception (late 2024).
• Annual sales — Rs 1,200+ crore in FY 2023-24.

Quality Assurance

Generic medicines are often stigmatised as "inferior" — PMBJP counters this through:

• NABL-accredited labs for testing.
• WHO-GMP certified manufacturers only.
• Batch testing mandatory.
• Same quality and efficacy as branded counterparts; same active pharmaceutical ingredient, same bioavailability.

Product Categories

JAKs stock medicines across:

• Anti-infectives — antibiotics, antimalarials, antivirals.
• Cardiovascular — antihypertensives, lipid-lowering.
• Anti-diabetic.
• Oncology — selected cancer medicines.
• Gastrointestinal.
• Respiratory.
• CNS and psychiatric.
• Pain and inflammation.
• Women's health — including the Suvidha sanitary napkin at Rs 1 per pad.
• Nutraceuticals and protein supplements.
• Surgical and consumables.

Suvidha Sanitary Napkin

Launched in 2018. Oxo-biodegradable. Priced at Rs 1 per pad. Over 55 crore pads sold by 2024.

Who Can Open a JAK?

• Individuals with D.Pharma/B.Pharma qualification.
• NGOs / Trusts / Cooperatives.
• Government hospitals and educational institutions.

Incentives

• Financial assistance of up to Rs 5 lakh for startup (Rs 2 lakh for furniture + Rs 3 lakh for operating costs — enhanced from earlier Rs 2.5 lakh).
• In NE states, tribal and hilly areas — additional incentives.
• 20% margin on MRP.
• Monthly incentive: 15% on monthly sales up to Rs 15,000.

Link with Public Health Goals

• Reduces OOPE — a structural target of National Health Policy 2017.
• Supports Universal Health Coverage by improving medicine access.
• Complements Ayushman Bharat PMJAY — hospitalisation + affordable outpatient medicines.
• Supports SDG 3.8 — UHC and access to essential medicines.

Challenges

Stockouts

• Supply chain disruptions — particularly for oncology and rare-disease drugs.
• Some kendras face frequent shortages.

Physician Prescription Habits

• Doctors often prescribe branded medicines.
• Generic prescription policies are uneven across states.
• National Medical Commission issued guidelines (August 2023) requiring doctors to prescribe generics; these were put on hold after professional pushback.

Consumer Trust

• Persistent perception that generics are "inferior".
• Need for sustained awareness campaigns.

Distribution

• Tier-III towns and rural areas — reach is expanding but uneven.
• Last-mile availability in remote districts limited.

Quality Perception

• Occasional quality-control lapses hurt overall trust.
• More transparency on batch testing needed.

Regulatory Coordination

• Coordination with CDSCO, state drug controllers, and private pharmacies needed.

Recent Reforms

• Budget 2024-25 — expansion target of 25,000 JAKs by 2026.
• Digital integration — e-Aushadhi portal for inventory and supply chain.
• PMBI restructuring — greater operational autonomy for expansion.
• Expanded product basket — more oncology and chronic disease medicines.

Comparison with Similar Schemes

• Tamil Nadu Medical Services Corporation (TNMSC) — public-sector drug procurement and distribution.
• Amma Marundhagam, Janata Bazaar — state-level generic stores.
• AIIMS and ESIC pharmacies — institution-based generic supply.

PMBJP complements rather than replaces these state and institutional networks.

Latest Developments (2024-26)

Expansion Target. 25,000 JAKs by 2026 confirmed in Budget 2024-25.

Suvidha Sales. Over 55 crore pads sold by end-2024.

Product Basket Expansion. Oncology medicines expansion to cover more life-saving drugs.

NMC Generic Prescription Guidelines. August 2023 regulations requiring generic prescription put on hold after pushback; modifications being discussed.

Digital e-Aushadhi. Real-time inventory tracking deployed across JAKs.

Ayushman Vay Vandana (2024). Extends PMJAY to senior citizens — complementary to PMBJP in reducing OOPE for chronic medication.

Caste Census 2025. Union Cabinet approved caste enumeration in the next national census (April 2025); healthcare affordability data will be refreshed.

MPI 2024. Global Multidimensional Poverty Index 2024 confirmed 415 million Indians exited multidimensional poverty between 2005-06 and 2019-21; health affordability is a key factor in sustained poverty exit.

Women's Reservation Act. The Nari Shakti Vandan Adhiniyam 2023 — post-delimitation, women's health and menstrual hygiene will likely see greater legislative focus.

Global Gender Gap Index 2024. India ranked 129/146; affordable menstrual hygiene products and reproductive health medicines are part of the gender equity agenda.

Policy Recommendations

• Physician prescription policy — generic prescription mandate in public facilities.
• Supply chain strengthening — buffer stocks for stockouts.
• Quality control transparency — public dashboard of batch tests.
• Awareness campaigns — addressing perception gap.
• Hospital integration — on-site JAKs at district hospitals, medical colleges, PHCs.
• Insurance coverage — link PMBJP purchases to health insurance reimbursements.
• E-pharmacy rules — enabling home delivery from JAKs.
• NGO and CSR partnerships — community-level expansion.

UPSC Relevance

GS Paper II — Governance, Social Justice

• Issues relating to development and management of social sector/services — health.
• Welfare schemes for vulnerable sections.

GS Paper III — Economy

• Pharma sector; IPR; medicine pricing.

Possible mains questions

1. "PMBJP is a structural intervention on out-of-pocket health expenditure. Examine its design and performance." (250 words)
2. "Generic medicines face stigma despite scientific equivalence. Discuss the reasons and remedies." (150 words)
3. "PMBJP and Ayushman Bharat PMJAY are complementary instruments for UHC. Evaluate." (150 words)

Prelims pointers. PMBJP (relaunched 2015-16); earlier Jan Aushadhi Scheme (2008); PMBI — Pharmaceuticals & Medical Devices Bureau of India; Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers; 12,500+ JAKs (end-2024); target 25,000 by 2026; Suvidha sanitary napkin (Rs 1/pad, 2018); e-Aushadhi portal; NMC generic prescription guidelines (August 2023 — on hold); SDG 3.8.

Essay themes. "Medicine without poverty"; "Generics are medicine too"; "Affordability and access".

PMBJP is a structural reform disguised as a pharmacy network. Its expansion over the next three years is one of the most direct levers India has to reduce catastrophic health expenditure.